Dimensional Fund Advisors LP Lowers Holdings in Corcept Therapeutics Incorporated $CORT

Key Points

• Dimensional Fund Advisors reduced its Corcept Therapeutics position by 4.1% in the first quarter, selling 67,198 shares and retaining 1.55 million shares valued at approximately $62.6 million. Institutional investors collectively own 93.61% of the company.
• Corcept reported a strong quarterly performance, with earnings of $0.36 per share versus the $0.02 consensus estimate and revenue of $256.15 million, up 31.7% year over year and above expectations of $221.15 million.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and average price target of $119.17, although the stock’s elevated valuation and recent insider sales—including 300,000 shares sold over three months—could concern investors.

Dimensional Fund Advisors LP reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,553,135 shares of the biotechnology company's stock after selling 67,198 shares during the period. Dimensional Fund Advisors LP owned approximately 1.45% of Corcept Therapeutics worth $62,597,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Pathstone Holdings LLC raised its holdings in shares of Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company's stock valued at $1,497,000 after acquiring an additional 144 shares in the last quarter. Gould Capital LLC increased its position in shares of Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 200 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Corcept Therapeutics by 3.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company's stock worth $240,000 after purchasing an additional 247 shares during the last quarter. Evergreen Capital Management LLC raised its stake in Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company's stock valued at $300,000 after purchasing an additional 248 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Corcept Therapeutics by 3.4% during the fourth quarter. Deutsche Bank AG now owns 8,446 shares of the biotechnology company's stock valued at $294,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 93.61% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CORT shares. UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a report on Thursday, May 28th. HC Wainwright upped their target price on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a "buy" rating in a research report on Thursday. Weiss Ratings reissued a "hold (c-)" rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Zacks Research upgraded Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, May 4th. Finally, Truist Financial upgraded Corcept Therapeutics to a "strong-buy" rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $119.17.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported second-quarter earnings of $0.36 per share, well above the $0.02 analyst consensus, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler initiated or reiterated an “Overweight” rating, adding to the bullish analyst sentiment surrounding Corcept’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.78 from $0.34 and lifted its full-year 2026 forecast to $2.15 from $0.80. The firm maintained a “Buy” rating and a $165 price target, implying continued confidence in near-term earnings momentum.
• Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s revised estimates imply strong 2026 earnings growth, but the firm reduced several 2027 quarterly forecasts and lowered FY2027 EPS to $3.95 from $5.38. This suggests expectations for longer-term growth have moderated.
• Negative Sentiment: Some investors may be concerned that the stock’s rapid rise has already priced in much of LIFYORLI’s potential. A recent analysis described the drug as likely to become a blockbuster but warned that Corcept’s valuation leaves limited room for disappointment. Corcept Therapeutics: LIFYORLI Is Likely a Blockbuster, But the Valuation Already Knows It

Corcept Therapeutics Stock Down 3.2%

Shares of NASDAQ:CORT opened at $114.49 on Friday. The stock has a market cap of $12.38 billion, a PE ratio of 272.60 and a beta of 0.47. The company's fifty day moving average is $84.77 and its 200 day moving average is $56.78. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $122.21.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company's revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. Sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.13 EPS for the current year.

Insider Activity at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total transaction of $1,862,600.00. Following the transaction, the insider directly owned 3,985 shares in the company, valued at $371,123.05. This trade represents a 83.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James N. Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total value of $832,000.00. Following the completion of the transaction, the director directly owned 1,094,543 shares in the company, valued at $91,065,977.60. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 300,000 shares of company stock worth $22,088,050 over the last three months. Corporate insiders own 20.70% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source